Search From Over Half a Million Titles


Pharmaceuticals and Healthcare » Pharmaceuticals » Hematology

Thalassemia - Market Insights, Epidemiology and Market Forecast – 2025

  • ID:RM0034243
  • Published: September-2017
  • Pages:70
  • DelveInsight
1 of 3

DelveInsight s Thalassemia - Market Insights, Epidemiology and Market Forecast - Market Insights, Epidemiology and Market Forecast 2025 report provides an overview of the disease and in depth research related to Thalassemia - Market Insights, Epidemiology and Market Forecast for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025.

This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Thalassemia - Market Insights, Epidemiology and Market Forecast. It enables understanding of the historical and forecasted epidemiological data for the diagnosed prevalent cases of Thalassemia - Market Insights, Epidemiology and Market Forecast for ........
Show More
1 of 3


1. Report Introduction
2. Thalassemia Market Overview at a Glance
2.1. Total Market Share Distribution of Thalassemia for 7 MM in 2016
2.2. Total Market Share Distribution of Thalassemia for 7 MM in 2025
3. Thalassemia
3.1.1. Overview
3.1.2. Symptoms
3.1.3. Pathophysiology
3.1.4. Staging
3.1.5. Diagnosis
3.1.6. Treatment
4. Epidemiology and Patient Population
4.1.1. United States
4.1.1.1. Diagnosed Cases of Thalassemia in United States
4.1.2. Germany
4.1.2.1. Diagnosed Cases of Thalassemia in Germany
4.1.3. France
4.1.3.1. Diagnosed Cases of Thalassemia in France
4.1.4. Italy
4.1.4.1. Diagnosed Cases of Thalassemia in Italy
4.1.5. Spain
4.1.5.1. Diagnosed Cases of Thalassemia in Spain
4.1.6. United Kingdom
4.1.6.1. Diagnosed Cases of Thalassemia in United Kingdom
5. Treatment Algorithm
5.1.1. Treatment Guidelines/Practices
6. Marketed Drugs for Thalassemia
6.1. Drug 1: Company A
6.1.1. Drug Description
6.1.2. Mechanism of Action
6.1.3. Regulatory Milestones
6.1.4. Advantages & Disadvantages
6.1.5. Safety and Efficacy
6.1.6. Product Profile
6.1.7. Patent Status
6.2. Drug 2: Company B
6.2.1. Drug Description
6.2.2. Mechanism of Action
6.2.3. Regulatory Milestones
6.2.4. Advantages & Disadvantages
6.2.5. Safety and Efficacy
6.2.6. Product Profile
6.2.7. Patent Status
7. Emerging Therapies
7.1. Drug 3: Company C
7.1.1. Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Product Profile
7.1.5. Launch Date
7.1.6. Clinical Development
7.1.7. Clinical Pipeline Activity
7.1.8. Ongoing Trials Information
7.1.9. Clinical Trial by Phase
7.2. Drug 4: Company B
7.2.1. Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Product Profile
7.2.5. Launch Date
7.2.6. Clinical Development
7.2.7. Clinical Pipeline Activity
7.2.8. Ongoing Trials Information
7.2.9. Clinical Trial by Phase
8. Overview of Total Thalassemia Market (2016 & 2025)
9. Thalassemia: Country-Wise Market Analysis
9.1. United States
9.1.1. Historical Market Size (2015-2016)
9.1.2. Forecasted Market Size (2017-2025)
9.2. Germany Market Size
9.2.1. Historical Market Size (2015-2016)
9.2.2. Forecasted Market Size (2017-2025)
9.3. France Market Size
9.3.1. Historical Market Size (2015-2016)
9.3.2. Forecasted Market Size (2017-2025)
9.4. United Kingdom Market Size
9.4.1. Historical Market Size (2015-2016)
9.4.2. Forecasted Market Size (2017-2025)
9.5. Spain Market Size
9.5.1. Historical Market Size (2015-2016)
9.5.2. Forecasted Market Size (2017-2025)
9.6. Italy Market Size
9.6.1. Historical Market Size (2015-2016)
9.6.2. Forecasted Market Size (2017-2025)
9.7. Japan Market Size
9.7.1. Historical Market Size (2015-2016)
9.7.2. Forecasted Market Size (2017-2025)
10. Market Drivers
11. Market Restraints
12. Appendix
13. Report Methodology
14. Consulting Services
15. Disclaimer
16. About DelveInsight


List of Tables

Table 1: Diagnosed Cases Thalassemia in United States (2015-2025)
Table 2: Diagnosed Cases Thalassemia in Germany (2015-2025)
Table 3: Diagnosed Cases Thalassemia in France (2015-2025)
Table 4: Diagnosed Cases Thalassemia in United Kingdom (2015-2025)
Table 5: Diagnosed Cases Thalassemia in Spain (2015-2025)
Table 6: Diagnosed Cases Thalassemia in Italy (2015-2025)
Table 7: Diagnosed Cases Thalassemia in Japan (2015-2025)
Table 8: List of Marketed Drugs for Thalassemia
Table 9: List of Pipeline Phase III Drugs for Thalassemia
Table 10: Drug 1, Clinical Trials by Zone, 2017
Table 11: Clinical Trials by Trial status, 2017
Table 12: Drug 2, Clinical Trials by Zone, 2017
Table 13: Clinical Trials by Trial status, 2017
Table 14: Drug 3, Clinical Trials by Zone, 2017
Table 15: Clinical Trials by Trial status, 2017
Table 16: United States Market Size of Thalassemia in USD, Million (2015-2025)
Table 17: Germany Market Size of Thalassemia in USD, Million (2015-2025)
Table 18: France Market Size of Thalassemia in USD, Million (2015-2025)
Table 19: United Kingdom Market Size of Thalassemia in USD, Million (2015-2025)
Table 20: Spain Market Size of Thalassemia in USD, Million (2015-2025)
Table 21: Italy Market Size of Thalassemia in USD, Million (2015-2025)
Table 22: Japan Market Size of Thalassemia in USD, Million (2015-2025)

List of Figures
Figure 1: Diagnosed Cases Thalassemia in United States (2015-2025)
Figure 2: Diagnosed Cases Thalassemia in Germany (2015-2025)
Figure 3: Diagnosed Cases Thalassemia in France (2015-2025)
Figure 4: Diagnosed Cases Thalassemia in United Kingdom (2015-2025)
Figure 5: Diagnosed Cases Thalassemia in Spain (2015-2025)
Figure 6: Diagnosed Cases Thalassemia in Italy (2015-2025)
Figure 7: Diagnosed Cases Thalassemia in Japan (2015-2025)
Figure 8: List of Marketed Drugs for Thalassemia
Figure 9: List of Pipeline Phase III Drugs for Thalassemia
Figure 10: Drug 1, Clinical Trials by Zone (%), 2017
Figure 11: Clinical Trials by Trial status, 2017
Figure 12: Drug 2, Clinical Trials by Zone (%), 2017
Figure 13: Clinical Trials by Trial status, 2017
Figure 14: Drug 3, Clinical Trials by Zone (%), 2017
Figure 15: Clinical Trials by Trial status, 2017
Figure 16: United States Market Size of Thalassemia in USD, Million (2015-2025)
Figure 17: Germany Market Size of Thalassemia in USD, Million (2015-2025)
Figure 18: France Market Size of Thalassemia in USD, Million (2015-2025)
Figure 19: United Kingdom Market Size of Thalassemia in USD, Million (2015-2025)
Figure 20: Spain Market Size of Thalassemia in USD, Million (2015-2025)
Figure 21: Italy Market Size of Thalassemia in USD, Million (2015-2025)
Figure 22: Japan Market Size of Thalassemia in USD, Million (2015-2025)
Thalassemia Market (7MM)
Thalassemia Market forecasting
Thalassemia Sales forecasting
Thalassemia Market segments
Thalassemia Epidemiology
Thalassemia Pipeline products and technologies
Thalassemia Competitive landscape
Thalassemia SWOT analysis
Thalassemia Market Driver s and barriers
Thalassemia Key Companies and Funding


List Of Tables

Table 1: Diagnosed Cases Thalassemia in United States (2015-2025)
Table 2: Diagnosed Cases Thalassemia in Germany (2015-2025)
Table 3: Diagnosed Cases Thalassemia in France (2015-2025)
Table 4: Diagnosed Cases Thalassemia in United Kingdom (2015-2025)
Table 5: Diagnosed Cases Thalassemia in Spain (2015-2025)
Table 6: Diagnosed Cases Thalassemia in Italy (2015-2025)
Table 7: Diagnosed Cases Thalassemia in Japan (2015-2025)
Table 8: List of Marketed Drugs for Thalassemia
Table 9: List of Pipeline Phase III Drugs for Thalassemia
Table 10: Drug 1, Clinical Trials by Zone, 2017
Table 11: Clinical Trials by Trial status, 2017
Table 12: Drug 2, Clinical Trials by Zone, 2017
Table 13: Clinical Trials by Trial status, 2017
Table 14: Drug 3, Clinical Trials by Zone, 2017
Table 15: Clinical Trials by Trial status, 2017
Table 16: United States Market Size of Thalassemia in USD, Million (2015-2025)
Table 17: Germany Market Size of Thalassemia in USD, Million (2015-2025)
Table 18: France Market Size of Thalassemia in USD, Million (2015-2025)
Table 19: United Kingdom Market Size of Thalassemia in USD, Million (2015-2025)
Table 20: Spain Market Size of Thalassemia in USD, Million (2015-2025)
Table 21: Italy Market Size of Thalassemia in USD, Million (2015-2025)
Table 22: Japan Market Size of Thalassemia in USD, Million (2015-2025)


List of Figures

Figure 1: Diagnosed Cases Thalassemia in United States (2015-2025)
Figure 2: Diagnosed Cases Thalassemia in Germany (2015-2025)
Figure 3: Diagnosed Cases Thalassemia in France (2015-2025)
Figure 4: Diagnosed Cases Thalassemia in United Kingdom (2015-2025)
Figure 5: Diagnosed Cases Thalassemia in Spain (2015-2025)
Figure 6: Diagnosed Cases Thalassemia in Italy (2015-2025)
Figure 7: Diagnosed Cases Thalassemia in Japan (2015-2025)
Figure 8: List of Marketed Drugs for Thalassemia
Figure 9: List of Pipeline Phase III Drugs for Thalassemia
Figure 10: Drug 1, Clinical Trials by Zone (%), 2017
Figure 11: Clinical Trials by Trial status, 2017
Figure 12: Drug 2, Clinical Trials by Zone (%), 2017
Figure 13: Clinical Trials by Trial status, 2017
Figure 14: Drug 3, Clinical Trials by Zone (%), 2017
Figure 15: Clinical Trials by Trial status, 2017
Figure 16: United States Market Size of Thalassemia in USD, Million (2015-2025)
Figure 17: Germany Market Size of Thalassemia in USD, Million (2015-2025)
Figure 18: France Market Size of Thalassemia in USD, Million (2015-2025)
Figure 19: United Kingdom Market Size of Thalassemia in USD, Million (2015-2025)
Figure 20: Spain Market Size of Thalassemia in USD, Million (2015-2025)
Figure 21: Italy Market Size of Thalassemia in USD, Million (2015-2025)
Figure 22: Japan Market Size of Thalassemia in USD, Million (2015-2025)

1 of 3

Type Delivery Format Details
Hard Copy A printed copy of the report will be shipped to you.
CD-ROM The report will be shipped to you in CD ROM format.
SINGLE USER Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows one specific user access to the product.
SITE LICENSE Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows all users within a given geographical location of your organization access to the product.
ENTERPRISEWIDE Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows all employees within your organization in different geographic locations access to the product.
1 - 5 USERS Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows up to five users have access to the product.
1 – 10 USERS Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows up to ten users have access to the product.
1 – 15 USERS Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows up to fifteen users have access to the product.
1 - 5 USERS Online Access (For Databases) Database is accessed online through a secure website. You will receive a username and password via email to access to the online directory. The license allows up to five users have access to the product.
1 - 10 USERS Online Access(For Databases) Database is accessed online through a secure website. You will receive a username and password via email to access to the online directory. The license allows up to ten users have access to the product.
1 - 15 USERS Online Access(For Databases) Database is accessed online through a secure website. You will receive a username and password via email to access to the online directory. The license allows up to fifteen users have access to the product.
1 - 5 USERS Electronic (Excel) The Excel spreadsheet will be emailed to you. The license allows up to five users have access to the product.

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-10 user licence, allowing up to ten users have access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-15 user licence, allowing up to fifteen users have access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-15 user licence, allowing up to fifteen users have access to the product.